Bob Goeltz
About Bob Goeltz
Bob Goeltz Chief Financial Officer of UNITY Biotechnology
Bob Goeltz most recently served as the Chief Financial Officer and Senior Vice President of UNITY Biotechnology. In this role, he was instrumental in shaping the company's financial strategy and overseeing its finance organization. His leadership was crucial during UNITY Biotechnology's IPO, guiding the company through the complexities of public offering.
CFO Leadership at CytomX Therapeutics
Prior to his tenure at UNITY Biotechnology, Bob Goeltz served as the Chief Financial Officer at CytomX Therapeutics. During his time at CytomX, he led the company's IPO and finance organization, ensuring a solid financial foundation for the company's operations. His strategic financial oversight contributed to the company's successful entry into the public market.
Bob Goeltz's Career at Amgen
Bob Goeltz spent 11 years at Amgen, where he held several significant positions. Notably, he served as the Chief Financial Officer of Onyx Pharmaceuticals after its acquisition by Amgen. His responsibilities at Amgen included senior financial roles in commercial and R&D finance, business development, and accounting. He was also involved in launching multiple oncology products, showcasing his expertise in the financial aspects of the pharmaceutical industry.
Bob Goeltz's Early Career and Education
Bob Goeltz began his career in the audit practice at EY, where he developed a strong foundation in finance and accounting. He then served as the Director of Finance for Tularik. Bob received his Master of Business Administration degree from UCLA’s Anderson School of Management and his Bachelor of Business Administration degree from Emory University’s Goizueta School of Business, reflecting his solid educational background in business administration.